FDA Requires Drug Interaction Studies for Potassium-Lowering Kayexalate

Drug Industry Daily
A A
The FDA is requiring Concordia Pharmaceuticals to conduct drug interaction studies with its potassium-lowering drug Kayexalate, after the agency’s review of just-approved Veltassa showed that drug bound to about half of the oral medications tested.

To View This Article:

Login

Subscribe To Drug Industry Daily